Oura Health

Oura sells the ring hardware at a one-time price of $299 or more, depending on finish, and charges a $5.99 monthly membership fee to access the full feature set, including detailed sleep and readiness analytics. CEO Tom Hale disclosed in December 2024 that annual revenue had reached approximately $500 million. This dual revenue stream distributes risk across device margins and recurring subscription income, a model that differentiates it from pure-play hardware companies like Fitbit pre-acquisition.

Oura's cap table includes Lifeline Ventures, Forerunner Ventures, Gradient Ventures (Google's AI fund), and a roster of celebrity backers including Shaquille O'Neal, Lance Armstrong, and Will Smith. Hale told Bloomberg in December 2024 that the company's valuation was near $5 billion. The company has not disclosed a precise ownership breakdown between founders, employees, and venture stakeholders.

The Gen3 Oura ring measures heart rate, heart rate variability, body temperature, respiratory rate, and movement via accelerometer and infrared PPG sensors. The data feeds three core daily scores: Sleep, Readiness, and Activity. Temperature sensing gained prominence during the covid-19 pandemic, when Oura partnered with the NBA and WNBA to monitor players for early signs of illness inside the 2020 Orlando bubble.

While all three track sleep and recovery metrics, Oura competes on form factor rather than feature parity — the ring is screenless, worn on the finger, and collects continuous passive data without notification distractions. That positioning attracts a different user profile, often professionals who already wear a traditional watch and prefer a secondary, minimalist health sensor. Whoop also uses a screenless model but relies on a wrist strap, trading optical finger placement for arm-band PPG.

As of December 2024, CEO Tom Hale publicly signaled the company was on a path toward a potential public listing, noting the $500 million revenue mark and near-$5 billion valuation. Oura has not filed any public registration documents, and no formal S-1 has emerged. The company's December 2024 Series D round provided sufficient capital to fund operations without immediate need for additional primary fundraising.

Oura's privacy policy states that user health data is not sold to advertisers or data brokers; the company's revenue model relies on hardware and subscription sales rather than data monetization. The firm maintains GDPR compliance for European users and HIPAA-aligned data handling for US enterprise partnerships, including the Department of Defense health surveillance contract disclosed in 2024. Oura has not yet qualified as a regulated medical device for FDA-cleared clinical use, though its temperature-sensing research has appeared in peer-reviewed studies by UCSF and West Virginia University.

Oura introduced the membership requirement with the Gen3 ring launch in October 2021, charging $5.99 monthly for full access to daytime heart rate, SpO2, and workout data. The move followed the hardware-only economics of Gen2 rings, which generated no post-purchase revenue. Subscription uptake helped push the company past $500 million in annual revenue by late 2024, according to Bloomberg reporting.